1921
Volume 88, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Wider availability of the live, attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine has facilitated introduction or expansion of immunization programs in many countries. However, information on their impact is limited. In 2006, Nepal launched a JE immunization program, and by 2009, mass campaigns had been implemented in 23 districts. To describe the impact, we analyzed surveillance data from 2004 to 2009 on laboratory-confirmed JE and clinical acute encephalitis syndrome (AES) cases. The post-campaign JE incidence rate of 1.3 per 100,000 population was 72% lower than expected if no campaigns had occurred, and an estimated 891 JE cases were prevented. In addition, AES incidence was 58% lower, with an estimated 2,787 AES cases prevented, suggesting that three times as many disease cases may have been prevented than indicated by the laboratory-confirmed JE cases alone. These results provide useful information on preventable JE disease burden and the potential value of JE immunization programs.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.12-0196
2013-03-06
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/88/3/464.html?itemId=/content/journals/10.4269/ajtmh.12-0196&mimeType=html&fmt=ahah

References

  1. Fischer M, Lindsey N, Staples JE, Hills S, , 2010. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 127.
  2. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS, , 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89: 766774.[Crossref]
  3. World Health Organization, 2005. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Wkly Epidemiol Rec 80: 242243.
  4. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilker WB, Pan XP, Yao YJ, Xu ZW, Halstead SB, , 1997. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 176: 13661369.[Crossref]
  5. Yaïch M, , 2009. Investing in vaccines for developing countries: how public-private partnerships can confront neglected diseases. Hum Vaccin 5: 368369.[Crossref]
  6. Kumar R, Tripathi P, Rizvi A, , 2009. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360: 14651466.[Crossref]
  7. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB, , 2007. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25: 50415045.[Crossref]
  8. Henderson A, Leake CJ, Burke DS, , 1983. Japanese encephalitis in Nepal. Lancet 2: 359360.
  9. Joshi DD, , 1995. Current status of Japanese encephalitis in Nepal. Southeast Asian J Trop Med Public Health 26 (Suppl 3): 3440.
  10. Pant GR, , 2006. A serological survey of pigs, horses, and ducks in Nepal for evidence of infection with Japanese encephalitis virus. Ann N Y Acad Sci 1081: 124129.[Crossref]
  11. Bista MB, Shrestha JM, , 2005. Epidemiological situation of Japanese encephalitis in Nepal. J Nep Med Assoc 44: 5156.
  12. Zimmerman MD, Scott RM, Vaughn DW, Rajbhandari S, Nisalak A, Shrestha MP, , 1997. Short report: an outbreak of Japanese encephalitis in Kathmandu, Nepal. Am J Trop Med Hyg 57: 283284.
  13. Basnyat B, Zimmerman MD, Shrestha Y, Scott RM, Endy TP, , 2001. Persistent Japanese encephalitis in Kathmandu: the need for immunization. J Travel Med 8: 270271.[Crossref]
  14. Partridge J, Ghimire P, Sedai T, Bista MB, Banerjee M, , 2007. Endemic Japanese encephalitis in the Kathmandu valley, Nepal. Am J Trop Med Hyg 77: 11461149.
  15. Bhattachan A, Amatya S, Sedai TR, Upreti SR, Partridge J, , 2009. Japanese encephalitis in hill and mountain districts, Nepal. Emerg Infect Dis 15: 16911692.[Crossref]
  16. Wierzba TF, Ghimire P, Malla S, Banerjee MK, Shrestha S, Khanal B, Sedai TR, Gibbons RV, , 2008. Laboratory-based Japanese encephalitis surveillance in Nepal and the implications for a national immunization strategy. Am J Trop Med Hyg 78: 10021006.
  17. Burke DS, Nisalak A, , 1982. Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol 15: 353361.
  18. World Health Organization, 2008. WHO-Recommended Standards for Surveillance of Selected Vaccine-Preventable Diseases. Report No: WHO/V&B/03.01. Available at: http://whqlibdoc.who.int/hq/2003/WHO_V&B_03.01.pdf. Accessed June 2, 2011.
  19. Andrus JK, Banerjee K, Hull BP, Smith JC, Mochny I, , 1997. Polio eradication in the World Health Organization South-East Asia Region by the year 2000: midway assessment of progress and future challenges. J Infect Dis 175 (Suppl 1): S89S96.[Crossref]
  20. World Health Organization Regional Office for South-East Asia, 2011. Malaria Situation in SEAR Countries: Nepal. Available at: http://www.searo.who.int/EN/Section10/Section21/Section340.htm. Accessed February 15, 2011.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.12-0196
Loading
/content/journals/10.4269/ajtmh.12-0196
Loading

Data & Media loading...

  • Received : 27 Mar 2012
  • Accepted : 09 Dec 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error